SEC Filing Summary: ADVENTRX Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. on November 3, 2010. The registrant is a Delaware corporation headquartered in San Diego, California. The report discloses a material event regarding the company's product development pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the company's product candidate ANX-530 (vinorelbine injectable emulsion), branded as Exelbine(TM). This submission occurred on November 3, 2010.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the NDA submission. No specific financial guidance, future outlook, or discussion of risks and contingencies is included within the text of this 8-K form. The submission of an NDA represents a significant step toward potential commercialization but does not guarantee FDA approval.
Investor Verification Checklist
- Verify the status of the NDA for ANX-530 (Exelbine(TM)) with the FDA.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on the application.
- Consult the company's most recent 10-K or 10-Q filings for current financial position and cash runway, as this 8-K contains no financial data.
- Monitor for future 8-K filings regarding FDA review decisions or potential delays.